Coherus BioSciences Stock (NASDAQ: CHRS) stock price, news, charts, stock research, profile.
Open | $1.960 |
Close | $2.040 |
Volume / Avg. | 907.176K / 2.715M |
Day Range | 1.930 - 2.060 |
52 Wk Range | 1.430 - 8.220 |
Market Cap | $231.537M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 41 |
Short Interest | 24.17% |
Days to Cover | 8.01 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Coherus BioSciences (NASDAQ: CHRS) through any online brokerage.
Other companies in Coherus BioSciences’s space includes: Zura Bio (NASDAQ:ZURA), Renovaro (NASDAQ:RENB), Galectin Therapeutics (NASDAQ:GALT), Adverum Biotechnologies (NASDAQ:ADVM) and Century Therapeutics (NASDAQ:IPSC).
The latest price target for Coherus BioSciences (NASDAQ: CHRS) was reported by HC Wainwright & Co. on Wednesday, March 20, 2024. The analyst firm set a price target for 11.00 expecting CHRS to rise to within 12 months (a possible 439.22% upside). 25 analyst firms have reported ratings in the last year.
The stock price for Coherus BioSciences (NASDAQ: CHRS) is $2.04 last updated April 26, 2024 at 4:20 PM EDT.
There are no upcoming dividends for Coherus BioSciences.
Coherus BioSciences’s Q1 earnings are confirmed for Friday, May 10, 2024.
There is no upcoming split for Coherus BioSciences.
Coherus BioSciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.